Pfizer's RSV vaccine cleared for use in seniors by FDA.

The FDA has approved Pfizer's Abrysvo vaccine to prevent respiratory disease RSV in older adults, marking the second authorized RSV shot for older adults in the US this month after GlaxoSmithKline's Arexvy. The vaccine is expected to be available before the start of next RSV season. RSV causes severe illness in older adults, resulting in hospitalizations and deaths. Pfizer's vaccine was found to be more than 85% effective in preventing severe lower respiratory tract illness in older adults.